{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:45:52Z","timestamp":1780461952257,"version":"3.54.1"},"reference-count":43,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T00:00:00Z","timestamp":1524096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The aim of this study was to compare the effects of the selective M3 muscarinic acetylcholine receptor antagonist darifenacin, oral hyoscine hydrobromide and placebo on motion sickness induced by cross\u2010coupled stimulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The effects of darifenacin 10\u00a0mg or 20\u00a0mg, hyoscine hydrobromide 0.6\u00a0mg and placebo were assessed in a randomized, double\u2010blind, four\u2010way cross over trial of 16 healthy subjects. Motion sickness, skin conductance (a measure of sweating) and psychomotor cognitive function tests were investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Hyoscine hydrobromide produced significantly increased tolerance to motion versus placebo (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05 to <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01). The motion protection effect of darifenacin (10 or 20\u00a0mg) was approximately one third that of hyoscine hydrobromide but was not significant versus placebo. Darifenacin and hyoscine hydrobromide both significantly reduced skin conductance versus placebo. Darifenacin produced either no effect or an enhanced effect on cognitive function in contrast to hyoscine hydrobromide, where there was significant impairment of psychomotor performance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results suggest that selective antagonism of the M3 receptor may not be important in the prevention of motion sickness. However, selective M3 antagonism does not impair cognitive function. These observations may be important given that long\u2010term treatment with non\u2010selective anti\u2010muscarinic agents such as oxybutynin may lead to an increased incidence of dementia.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13579","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T21:26:37Z","timestamp":1520630797000},"page":"1535-1543","source":"Crossref","is-referenced-by-count":18,"title":["The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance &amp; cognitive function"],"prefix":"10.1111","volume":"84","author":[{"given":"John F.","family":"Golding","sequence":"first","affiliation":[{"name":"Department of Psychology, Faculty of Science &amp; Technology University of Westminster  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Wesnes","sequence":"additional","affiliation":[{"name":"Medical School University of Exeter  Exeter UK"},{"name":"Wesnes Cognition Ltd  Streatley\u2010on\u2010Thames UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Leaker","sequence":"additional","affiliation":[{"name":"Nephro\u2010Urology Clinical Trials Ltd.  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197917060-00003"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.30.040190.003221"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988118900300401"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000117954"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00176487"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2010.06.008"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903260790"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00606.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.018"},{"key":"e_1_2_8_11_1","first-page":"36","article-title":"A pilot study of the effects of multiple doses of the M3 muscarinic receptor antagonist darifenacin on ambulatory parameters of detrusor activity in patients with detrusor instability","volume":"14","author":"Rosario DJ","year":"1995","journal-title":"Neurol Urodyn"},{"key":"e_1_2_8_12_1","unstructured":"Novartis.Enablex (Darifenacin hydrobromide) drug approval 2005[online]. Available athttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/21\u2010513_Enablex.cfm."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645040-00001"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470020206"},{"key":"e_1_2_8_15_1","first-page":"165","article-title":"Phasic skin conductance activity and motion sickness","volume":"63","author":"Golding JF","year":"1992","journal-title":"Aviat Space Environ Med"},{"key":"e_1_2_8_16_1","first-page":"491","article-title":"comparison of the nauseogenic potential of low\u2010frequency vertical versus horizontal linear oscillation","volume":"63","author":"Golding JF","year":"1992","journal-title":"Aviat Space Environ Med"},{"key":"e_1_2_8_17_1","first-page":"3","article-title":"Electrodermal activity","author":"Venables PH","year":"1980","journal-title":"Techniques Psychophysiol"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1990.sp018020"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1974.tb02285.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1935-2"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470030106"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00131.x"},{"key":"e_1_2_8_23_1","first-page":"711","article-title":"A computerized system for the assessment of drug\u2010induced performance changes in young, elderly or demented populations","volume":"27","author":"Simpson P","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.166"},{"key":"e_1_2_8_25_1","volume-title":"Human psychopharmacology: Measures and methods","author":"Wesnes KA","year":"1987"},{"key":"e_1_2_8_26_1","volume-title":"Practical aspects of memory: current research and issues","author":"Wesnes KA","year":"1988"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13878"},{"key":"e_1_2_8_29_1","first-page":"47","article-title":"The effect of a selective muscarinic receptor antagonist and scopolamine on motion sickness, skin conductance and heart rate in humans","volume":"476","author":"Stott J","year":"1994","journal-title":"J Physiol"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(91)90565-J"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-6618(05)80082-9"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(03)45003-6"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706780"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn992"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-013-1406-z"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145712000752"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7119.1363"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00752.x"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(94)00021-J"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704897"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1208\/ps030430"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03961.x"},{"key":"e_1_2_8_43_1","unstructured":"AllenMJ JohnsonBF LeakerBR WallisRM.Method of enhancing cognition. In: Google Patents 1998."},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.7663"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13579","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T05:06:03Z","timestamp":1694667963000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,19]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/bcp.13579"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13579","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,19]]}}}